Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

医学 ROS1型 内科学 肺癌 肿瘤科 不利影响 人口 癌症 临床试验 胃肠病学 腺癌 环境卫生
作者
Yun Fan,Alexander Drilon,Chao‐Hua Chiu,Herbert H. Loong,Salvatore Siena,Maciej Krzakowski,Rafał Dziadziuszko,Harald Zeuner,Cloris Xue,Matthew Krebs
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:25 (2): e81-e86.e4 被引量:1
标识
DOI:10.1016/j.cllc.2023.12.001
摘要

•Genetic alterations in ROS1 can lead to the expression of oncogenic fusion proteins in multiple tumor types, including in 1% to 2% of non–small-cell lung cancer (NSCLC) cases. Approximately 40% of patients with ROS1 fusion-positive NSCLC have baseline central nervous system (CNS) metastases, indicating the need for a treatment with CNS activity. Entrectinib, a potent ROS1 tyrosine kinase inhibitor with activity in the CNS, has previously demonstrated overall and intracranial efficacy, and a manageable safety profile, in patients with ROS1 fusion-positive NSCLC.•In this updated analysis with 4 additional patients and longer follow-up, the objective response rate (ORR) in the efficacy-evaluable population (N = 172) was 67%; median duration of response (DoR) was 20.4 months, and median progression-free survival was 16.8 months. In 51 patients with baseline CNS metastases, intracranial ORR was 49% and median intracranial DoR was 12.9 months. In a subgroup analysis in patients who had not received any prior systemic therapy in the metastatic setting, ORR was similar to that in the efficacy-evaluable population, but median DoR was numerically longer at 35.6 months. Most treatment-related adverse events were grade 1 to 2 and nonserious.•These data reinforce previous findings on the use of entrectinib for the treatment of patients with ROS1 fusion-positive NSCLC, and support current guidelines that recommend entrectinib as a first-line treatment option for these patients, including those with baseline CNS metastases. •Genetic alterations in ROS1 can lead to the expression of oncogenic fusion proteins in multiple tumor types, including in 1% to 2% of non–small-cell lung cancer (NSCLC) cases. Approximately 40% of patients with ROS1 fusion-positive NSCLC have baseline central nervous system (CNS) metastases, indicating the need for a treatment with CNS activity. Entrectinib, a potent ROS1 tyrosine kinase inhibitor with activity in the CNS, has previously demonstrated overall and intracranial efficacy, and a manageable safety profile, in patients with ROS1 fusion-positive NSCLC.•In this updated analysis with 4 additional patients and longer follow-up, the objective response rate (ORR) in the efficacy-evaluable population (N = 172) was 67%; median duration of response (DoR) was 20.4 months, and median progression-free survival was 16.8 months. In 51 patients with baseline CNS metastases, intracranial ORR was 49% and median intracranial DoR was 12.9 months. In a subgroup analysis in patients who had not received any prior systemic therapy in the metastatic setting, ORR was similar to that in the efficacy-evaluable population, but median DoR was numerically longer at 35.6 months. Most treatment-related adverse events were grade 1 to 2 and nonserious.•These data reinforce previous findings on the use of entrectinib for the treatment of patients with ROS1 fusion-positive NSCLC, and support current guidelines that recommend entrectinib as a first-line treatment option for these patients, including those with baseline CNS metastases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助小不溜采纳,获得10
刚刚
zxc完成签到,获得积分20
2秒前
lixiangrui110完成签到,获得积分10
3秒前
3秒前
34完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
5秒前
5秒前
草莓奶昔完成签到 ,获得积分10
5秒前
源缘完成签到 ,获得积分10
6秒前
英俊的铭应助稗子采纳,获得10
6秒前
zhaoyuli发布了新的文献求助10
6秒前
9秒前
10秒前
10秒前
11秒前
11秒前
JamesPei应助比巴卜采纳,获得10
11秒前
Lucas应助沟通亿心采纳,获得10
11秒前
lizzie发布了新的文献求助10
12秒前
酷波er应助亮亮采纳,获得10
13秒前
伶俐雅柏完成签到,获得积分10
13秒前
糖璃发布了新的文献求助10
14秒前
啊啊发布了新的文献求助10
14秒前
longlong发布了新的文献求助10
15秒前
夏xia完成签到 ,获得积分10
16秒前
李科研发布了新的文献求助10
16秒前
碳烤小肥肠完成签到,获得积分10
19秒前
yx_cheng应助科研通管家采纳,获得10
19秒前
领导范儿应助科研通管家采纳,获得10
19秒前
yx_cheng应助科研通管家采纳,获得10
19秒前
SciGPT应助科研通管家采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
石石石发布了新的文献求助10
20秒前
20秒前
20秒前
20秒前
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403